SCHEMBL5653456

SCHEMBL5653456

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc(F)c(Cl)cc3[nH]2)c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 2/20 0.44
PRSS12 P56730 1/20 0.43
GAA P10253 2/20 0.42
HDAC6 Q9UBN7 2/20 0.41
MET P08581 1/20 0.41
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NSD2 O96028 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
FLT3 P36888 1/20 0.40
USP7 Q93009 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653446 0.97 TP53 (0.44) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5652128 0.92 TP53 (0.46) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5651973 0.91 HTT (0.47) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5648694 0.91 TP53 (0.47) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5651963 0.89 HTT (0.47) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5652123 0.89 TP53 (0.46) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5653858 0.88 PRMT5 (0.47) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5648813 0.88 PRSS12 (0.49) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5652330 0.88 TP53 (0.42) TP53SMN1; SMN2HTTPRSS12GAA
SCHEMBL5653719 0.88 FLT3 (0.51) PRSS12FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 TP53 4051/4885SMN1; SMN2 1510/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.